peptide whereas more C-terminally located domain enriched with acidic amino acids acts as translocation arrest sequence. 11 Upon mitochondrial entry, APP forms stable translocation intermediate complexes with mitochondrial translocase of the outer membrane (TOM) as well as links together translocases the outer and the inner membranes. 4, 11 Complexes between mitochondrial protein translocases and APP were particularly abundant in the affected areas of the brains of patients with AD suggesting connection between mitochondrial APP accumulation and AD pathology in the brain. 4 APP accumulated in the mitochondrial import channels can be degraded by several mitochondrial proteases including HtrA2/Omi and gamma secretase. 5, 12 At present, factors contributing to mitochondrial APP accumulation under AD conditions are not known. Genetic variations in components of mitochondrial protein translocase can result in lower efficiency of mitochondrial protein import and APP accumulation in the import channels. 13 AD-associated mutations in the mitochondrial protein degradation system 14 can shift the APP uptake/ degradation balance towards mitochondrial APP accumulation. Different environmental factors can also contribute to the mitochondrial APP accumulation. For example, high intracellular cholesterol level, a risk factor for development of Alzheimer's disease, has been shown to affect APP secretion, post-translational modification and intracellular trafficking. 15 Although the molecular determinants for Ab mitochondrial import are not known, mitochondrial protein translocase also participates in the import of Ab peptide 16 suggesting that reduction in APP and Ab mis-targeting can promote neuronal survival under AD conditions.
Nuclear-encoded proteins destined to mitochondria enter the organelle via the TOM complex consisting of protein-conducting channel formed by Tom40, two primary receptors, Tom20 and Tom70, the central receptor Tom22 and several adaptor subunits of small molecular mass. 17 The majority of mitochondrial precursor proteins enter the organelle via Tom20 receptor whereas hydrophobic mitochondria-destined proteins with internal targeting signals preferentially follow Tom70 receptor pathway. 17 Cytosolic molecular chaperones Hsp70 and Hsp90 as well as other specific factors in cytosol participate in targeting of newly synthesized proteins to the Tom70 receptor. 18, 19 The interaction is mediated by the short C-terminal acidic peptide-EEVD identical in Hsp70 and Hsp90 which binds to the tetratricopeptide repeat motif (TPR) of Tom70 receptor by dicarboxylate clamp mechanism. 19, 20 
| Chemicals
All common chemicals were purchased from Sigma (St. Louis, MO, USA) unless stated otherwise. and protease inhibitor cocktail were added to prevent proteolysis.
| Peptides and peptide coupling to HRP
The suspension was centrifuged for 30 minutes 50 000 9 g to remove cell debris, and supernatant was loaded onto 1 mL Gst-trap 4B column (GE Healthcare Uppsala, Sweden 
| SDS-PAGE and Western blot analysis
Protein ( 
| Cytochrome oxidase activity assay
Cytochrome c (2.7 mg/mL) was reduced by incubation with DTT, and excess of reducing agent was removed by gel filtration on PD-10 column (GE Healthcare, Uppsala, Sweden). Cytochrome oxidase activity was measured by decrease in absorbance of ferrocytochrome c at 550 nm. Mouse brain mitochondria were isolated according to Ref. [4] . Isolated mitochondria from non-Tg mice, vehicle-treated 5xFAD mice and 5xFAD mice treated with GMP-1 were diluted in the buffer containing 10 mmol/L Tris-HCl, pH 7.0, 0.5 mol/L sucrose, 0,05% Triton X-100 to concentration 0.5 mg/mL.
After addition of ferrocytochrome c, latency in 550 nm absorbance was immediately measured. Each group included six mice, and experiments were performed in triplicate. Data are presented as mean AE SEM. P < .05 was considered to be statistically significant.
| Transgenic drosophila experiments
The fly lines containing single and double copies of a signal-peptideAb 42 transgene were generated as described in Ref. [24] . The fly line expressing in the neurons dimer Ab 42 peptide connected via a linker of 12 amino acids (T-Ab 42 ) was generated as described in Ref. [25] .
Flies were maintained on the standard food containing 1% Agar, 8%
Brewer's yeast, 8% fructose, 5% potato dry powder, 0.05% Nipagin, 0.1% ascorbate in humidified atmosphere at 25°C. Indicated amounts of compounds were added directly to the food during solidification. The fly mobility assay represents the percentage of flies that able to cross the line at 8 cm from the bottom of test tube in 10 seconds. Six independent measurements for each group were performed. Data are presented as mean AE SEM. P < .05 was considered to be statistically significant. The survival assay in flies expressing tandem Ab 42 in the neurons was calculated as percentage of adult flies carrying the transgene, plain wings phenotype, to the total number of hatched flies with plain + curly wings phenotype.
Six independent measurements for each group were performed.
Data are presented as mean AE SEM. P < .05 was considered to be statistically significant.
| In vivo mice experiments
Experiments with control and 5xFAD, APP/presenilin-1 transgenic mice 26 Mice were trained and tested on 2 consecutive days. On the training day, mice received a foot shock (0.5 mA, 2 seconds) 5 seconds after being placed into the conditioning chamber. Thirty seconds afterwards, they were returned to their home cage again. Twenty-four hours after training, mice were tested by being returned to the con- group values were calculated using the individual means. Data were tested for normality using a Kolmogorov-Smirnov test; differences between groups were calculated by one-way ANOVA followed by a Newman-Keuls post-hoc test, the alpha-error set to 0.05. (Figure 2A and B) . We We have also used a T-Ab 1-42 drosophila model to assess the effect GMP-1 on toxicity of aggregation-prone Ab species. It has been previously shown that hatching of T-Ab 1-42 -expressing flies was compromised at 25°C in comparison with 18°C incubation temperatures. 25 We have observed that addition of GMP-1 into the food of T-Ab 1-42 -expressing flies growing at 25°C rescued hatching to the levels similar to 18°C ( Figure 3B ).
These results suggest neuroprotective effect of GMP-1 in drosophila Ab 1-42 -expressing models. 
Effect on behaviour, memory, amyloid beta accumulation, neuroinflammation and mitochondrial function
The 5xFAD model is a double transgenic APP/PS1 mouse model that coexpresses five AD mutations leading to accelerated plaque formation and increased Ab 1-42 production. 26 Amyloid deposition and gliosis begin at 2 months accompanied by robust neuronal loss starting from 3 months of age as well as cognitive and memory decline. F I G U R E 6 Immunohistochemical assessment of GMP-1 treatment on amyloid plaques accumulation and neuroinflammation. A, Amyloid plaque area in cortex and hippocampus measured as anti-APP (6E10) antibody staining. Placebo-treated, GMP-1 chronically treated, GMP-1 acutely treated 5xFAD mice as well as non-transgenic animals indicated as A, B, C and D, respectively. Differences between groups were calculated by one-way ANOVA followed by a Newman-Keuls post-hoc test, the alpha-error set to 0.05. *P < .05, ***P < .001, n = 6. B, Representative images of brain slices from 6-month-old 5xFAD mice stained with 6E10 antibodies and Alexa Fluor â 488 secondary antibodies.
Arrows indicate area of cortex (C) and hippocampus (H). C, Astrocytosis in the cortex and hippocampus measured as anti-GFAP antibody staining. Placebo-treated, GMP-1 chronically treated, GMP-1 acutely treated 5xFAD mice as well as non-transgenic animals indicated as A, B, C and D, respectively. Differences between groups were calculated by one-way ANOVA followed by a Newman-Keuls post-hoc test, the alpha-error set to 0.05. *P < .05, **P < .01, n = 6. D. Microglia activation in the cortex and hippocampus measured as anti-CD11b antibody staining. Placebo-treated, GMP-1 chronically treated, GMP-1 acutely treated 5xFAD mice as well as non-transgenic animals indicated as A, B, C and D, respectively. Differences between groups were calculated by one-way ANOVA followed by a Newman-Keuls post-hoc test, the alpha-error set to 0.05. **P < .01, n = 6 littermates ( Figure 4A ). Next, we tested 5xFAD mice with hippocam- ing. It has to be mentioned that GMP-1 interaction with TPR domains has relatively low affinity for Tom70 as well as relatively low specificity towards other TPR proteins such as PP5, FKBP51 and Tom34.
We are currently executing hit-to-lead programme to identify compounds with improved affinity/specificity as well as their drug-likeness. GMP-1 analogues have previously been patented and described as CNS drugs that have depressing and ataractic effect and could be used to relieve anxiety and tension states (patent US4109087 A, 1978). They also reduced local inflammation measured by carageenan oedema assay and delayed hypersensitivity test in rats (patent US4109087 A, 1978). It is well known that progressive Ab accumulation in the brain triggers neuronal hyperexcitation both in AD animal models and patients with AD often resulting in seizures 31, 32 ; therefore, With regard to mitochondrial metabolism, we have observed restoration of cytochrome oxidase activity in the GMP-1-treated mice. We have also found reduced levels of mitochondria-associated APP in the F I G U R E 7 Cytochrome oxidase activity measurement in isolated brain mitochondria. Result bars represent specific activity (means AE SEM) of cytochrome oxidase measured as described in Materials and Methods. *P < .05, n = 6 GMP-1-treated mice; however, because of the relatively low number of studied animals, the values did not reach statistical significance.
Finally, we have proposed a new treatment strategy for AD protecting mitochondrial function via modulation of molecular chaperone network. GMP-1 exhibits neuroprotective effect in drosophila and mice AD models resulting in increased fly viability and memory improvement in 5xFAD mice.
